Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mallinckrodt Must Publicize Price Increases In Wake Of DOJ Settlement On Medicaid Rebates

Executive Summary

Under corporate integrity agreement, Mallinckrodt must post proposed list price increases for Acthar and other non-generic products along with a link to executive compensation. $234m settlement resolves allegations it underpaid Medicaid rebates resulting from Acthar price hikes.

You may also be interested in...



Terlivaz Approved By FDA As Mallinckrodt Seeks To Advance New Business Strategy

Terlivaz is the first product approved to improve kidney function in adults with hepatorenal syndrome (HRS). The approval is a milestone in a long regulatory road for the drug.

Nielsen Follows Olafsson From Hikma Under Mallinckrodt Shake-Up

After emerging successfully from bankruptcy proceedings, and appointing the thoroughly experienced Siggi Olafsson as its CEO, Mallinckrodt has unveiled a new senior leadership team.

Mallinckrodt Finalizes Bankruptcy Filing And Opioid, Acthar Settlements

The company will pay $1.6bn to settle opioid litigation and $260m to settle a Medicaid rebate dispute related to Acthar Gel under a restructuring support agreement.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS145835

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel